Agilent and TIFR Hyderabad join hands to boost metabolism and health research

WHO, ITU, and WIPO release new report on AI use in traditional medicine

The global TCIM market is expected to reach nearly US$ 600 billion by 2025

AstraZeneca's Baxdrostat met the primary and all secondary endpoints in BaxHTN Phase III trial

Baxdrostat demonstrated a statistically significant and clinically meaningful reduction of systolic blood pressure compared with placebo

EU launches strategies to strengthen crisis readiness and health security

The Medical Countermeasures Strategy focuses on strengthening the EU’s preparedness for health crises

argenx advances clinical development of agonist antibody for myasthenic syndromes

ARGX-119 is the sixth molecule developed through our Immunology Innovation Program to show proof-of-concept

India exports US$ 4,961 million pharmaceutical during April–May 2025: Pharmexcil

Enhance strategies to drive sustainability, global Reach and digital transformation for a trillion-dollar future

Philogen withdraws marketing authorization application for Nidlegy in EU

The company's decision to withdraw the MAA was due to the timing of the availability of Chemistry Manufacturing and Controls

Roche to advance prasinezumab into Phase III development for early-stage Parkinson's disease

Prasinezumab is a potential first-in-class anti-alpha-synuclein antibody, targeting a known biological driver of Parkinson’s disease progression

Biocon Foundation launches BioWISE Program to empower women in STEM

25 women students to receive internship, training, and mentorship in Life Sciences segment

Merck presents positive Phase 2 data for Enpatoran demonstrating reduction in disease activity in patients with CLE and SLE with active lupus rash

Enpatoran is a potential first-in-class oral therapy for CLE and SLE that is thought to selectively block the activation of Toll-like receptors (TLR)7 and TLR8